



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: B. Tjellstrom, et al.

Examiner: J. H. Roark

Serial No.: 09/925,671

Art Unit: 1644

Filing Date: August 9, 2001

Docket: 11133z

For: ORAL IMMUNOGLOBULIN
TREATMENT FOR INFLAMMATORY
BOWEL DISEASE

Date: April 30, 2003

RECEIVED

MAY 06 2003

Commissioner for Patents
Washington, DC 20231

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§1.97 and 1.98, it is requested that the following disclosures, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. Tjellstrom B. et al. (1997) "Oral Immunoglobulin Treatment in Crohn's disease", Acta Paediatr 86: 221-223;
2. U.S. Patent No. 5,833,984, dated 11/10/98 to Eibl et al.;
3. U.S. Patent No. 6,090,380, dated 7/18/00 to Weisbart;

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on April 30, 2003.

Dated: April 30, 2003


Michelle Mustafa

4. European Patent Application No. EP 1044690A1, published 2000-10-18;
5. International Patent Application No. WO 0062806, published 2000-10-26;
and
6. Ruuska, T. et al. (1994) "Exclusive Whole Protein Enteral Diet Versus Prednisolone in the Treatment of Acute Crohn's Disease in Children", Journal of Pediatric Gastroenterology and Nutrition 19(2): 175-180.

The references were cited in an International Search Report received from the International Searching Authority dated March 31, 2003. Applicants are submitting copies of the above-cited references, together with a copy of the Search Report. The relevance of the above-identified references has been described in the Search Report.

Consideration of this Information Disclosure Statement is respectfully requested, since the art provided may be material to the examination of the present application as defined under 37 C.F.R. §1.56.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,



Frank S. DiGiglio
Reg. No. 31,346

Scully, Scott, Murphy & Presser
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343
FSD/XZ:ab


1544

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))			Docket No. 11133z
In Re Application Of: B. Tjellstrom, et al.			
Serial No. 09/925,671	Filing Date August 9, 2001	Examiner J. H. Roark	Group Art Unit 1644
Title: ORAL IMMUNOGLOBULIN TREATMENT FOR INFLAMMATORY BOWEL DISEASE			
			RECEIVED MAY 06 2003
Address to: Assistant Commissioner for Patents Washington, D.C. 20231			
TECH CENTER 1600/2900			
37 CFR 1.97(b)			
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.			
37 CFR 1.97(c)			
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:			
<input type="checkbox"/> the statement specified in 37 CFR 1.97(e);			
OR			
<input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).			

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
11133z

In Re Application: **B. Tjellstrom, et al.**



Serial No.
09/925,671

Filing Date
August 9, 2001

Examiner
J. H. Roark

Group Art Unit
1644

ORAL IMMUNOGLOBULIN TREATMENT FOR INFLAMMATORY BOWEL DISEASE

RECEIVED

MAY 06 2003

Payment of Fee

TECH CENTER 1600/2900

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. **19-3886/RCT** as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited
April 30, 2003 with the U.S. Postal Service
as first class mail under 37 C.F.R. 1.8 and is
addressed to the Assistant Commissioner for Patents,
Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Michelle Mustafa

Typed or Printed Name of Person Mailing Certificate


***This certificate may only be used if paying by deposit account.**

Signature

Dated: **April 30, 2003**

Frank S. DiGiglio
Registration No. 31,346
Scully, Scott, Murphy & Presser
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343

cc: **FSD/XZ:ab**



#10

Sheet 1 of 1

Form PTO-1449 (REV. 7-80) LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Atty. Docket No. 11133z	Serial No. 09/925,671
	Applicant B. Tjellstrom, et al.		
	Filing Date August 9, 2001	Group 1644	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLAS S	FILING DATE (if appropriate)
	AA	5,833,984	11/10/98	Eible et al.			RECEIVED
	AB	6,090,380	7/18/00	Weisbart			MAY 06 2003
	AC						TECH CENTER 1600/2900
	AD						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLAS S	TRANSLATION	
							YES	NO
	AK	EP 1044690A1	2000-10-18	EPO				
	AL	WO 0062806	2000-10-26	PCT				

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AP	Tjellstrom B. et al. (1997) "Oral Immunoglobulin Treatment in Crohn's disease", <u>Acta Paediatr</u> 86: 221-223
	AQ	Ruuska, T. et al. (1994) "Exclusive Whole Protein Enteral Diet Versus Prednisolone in the Treatment of Acute Crohn's Disease in Children", <u>Journal of Pediatric Gastroenterology and Nutrition</u> 19(2): 175-180
	AR	
	AS	
	AT	

EXAMINER	DATE CONSIDERED
-----------------	------------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.